Date published: 2026-5-18

1-800-457-3801

SCBT Portrait Logo
Seach Input

1110021L09Rik Inhibitors

Chemical inhibitors of 1110021L09Rik can exert their inhibitory effects through various mechanisms related to the transport and storage of monoamines. Reserpine functions by binding irreversibly to vesicular monoamine transporters, and although 1110021L09Rik is not specifically documented to be affected, by analogy, reserpine's action would likely deplete monoamines in the synaptic vesicles, leading to functional inhibition of 1110021L09Rik. Similarly, tetrabenazine reversibly binds to VMAT2, reducing the uptake of monoamines into synaptic vesicles and would be expected to exert a comparable effect on 1110021L09Rik. Lobeline also inhibits the packaging of monoamines into vesicles, thus directly inhibiting the function of 1110021L09Rik. Ketanserin, while primarily a serotonin receptor antagonist, can elevate extracellular serotonin, which may cause a feedback inhibition effect on 1110021L09Rik.

Other inhibitors like iproniazid and pargyline target monoamine oxidase, increasing monoamine levels in the cytoplasm and possibly leading to a reduced functional requirement for 1110021L09Rik in packaging these neurotransmitters. Fenfluramine releases serotonin and inhibits its reuptake, which can lead to an increase in extracellular serotonin, again potentially triggering feedback inhibition mechanisms that would reduce the functional activity of 1110021L09Rik. Clorgyline, being a selective MAO-A inhibitor, would similarly elevate intracellular monoamine levels, diminishing the need for monoamine transport by 1110021L09Rik. Methyldopa, by interfering with the normal monoamine uptake process, implies a reduction in the functional necessity for 1110021L09Rik activity. Methyldopa acts as a precursor to a false neurotransmitter, which could result in decreased uptake by 1110021L09Rik. Lastly, carbidopa, by inhibiting peripheral aromatic L-amino acid decarboxylase, may increase L-DOPA levels outside the brain, affecting the synthesis and consequently the transport of monoamines, indirectly inhibiting the functional role of 1110021L09Rik.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Reserpine

50-55-5sc-203370
sc-203370A
1 g
5 g
$137.00
$414.00
1
(2)

Reserpine binds irreversibly to vesicular monoamine transporters, including VMAT2, which is similar to the function of 1110021L09Rik in monoamine transport. This binding inhibits the uptake of monoamines into synaptic vesicles, depleting the monoamines and inhibiting the function of the protein.

Tetrabenazine

58-46-8sc-204338
sc-204338A
10 mg
50 mg
$168.00
$721.00
(1)

Tetrabenazine inhibits vesicular monoamine transport by reversibly binding to VMAT2, which consequently reduces uptake of monoamines into synaptic vesicles and depletes monoamine neurotransmitter levels, thus functionally inhibiting 1110021L09Rik.

Ketanserin

74050-98-9sc-279249
1 g
$700.00
(0)

Ketanserin is a serotonin receptor antagonist that also blocks the serotonin transporter. By inhibiting the reuptake of serotonin, it could increase extracellular serotonin levels, potentially leading to a downregulation of vesicular transporters like 1110021L09Rik due to feedback inhibition.

Methylene blue

61-73-4sc-215381B
sc-215381
sc-215381A
25 g
100 g
500 g
$43.00
$104.00
$328.00
3
(1)

Methylene Blue inhibits guanylate cyclase, which could lead to altered cyclic GMP levels and impact the pathways involving monoamine transport, possibly leading to the inhibition of 1110021L09Rik activity in monoamine packaging.

Pargyline hydrochloride

306-07-0sc-215676
sc-215676A
500 mg
1 g
$39.00
$82.00
2
(1)

Pargyline is a monoamine oxidase inhibitor. By preventing the breakdown of monoamines, it could elevate intracellular levels, potentially reducing the demand on vesicular transporters like 1110021L09Rik and thereby functionally inhibiting them.

S(−)-Carbidopa

28860-95-9sc-200749
sc-200749A
25 mg
100 mg
$96.00
$275.00
5
(0)

Carbidopa inhibits aromatic L-amino acid decarboxylase outside the blood-brain barrier, which could lead to increased peripheral L-DOPA levels, influencing monoamine synthesis and potentially inhibiting vesicular transporters like 1110021L09Rik indirectly.